Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-07-11 5:27 pm Sale | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 100 100.000% | -57,345,694 (-100.00%) | View |
| 2022-05-23 8:55 pm Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 57,345,794 74.930% | 0 (Unchanged) | View |
| 2022-03-15 09:00 am Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 57,345,794 74.930% | 0 (Unchanged) | View |
| 2022-02-18 8:47 pm Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 57,345,794 75.150% | 0 (Unchanged) | View |
| 2022-02-14 11:43 am Sale | 13G | Entasis Therapeutics Holdings Inc. ETTX | EVENTIDE ASSET MANAGEMENT LLC | 590,602 1.200% | -288,939 (-32.85%) | View |
| 2022-02-01 6:34 pm Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 57,345,794 75.150% | 0 (Unchanged) | View |
| 2022-01-18 5:27 pm Purchase | 13D | Entasis Therapeutics Holdings Inc. ETTX | TPG GP A LLC | 1,020,748 2.100% | 1,020,748 (New Position) | View |
| 2021-06-11 5:37 pm Purchase | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 57,345,794 75.500% | 12,537,950 (+27.98%) | View |
| 2021-05-03 5:19 pm Purchase | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 44,807,844 70.600% | 7,462,050 (+19.98%) | View |
| 2021-03-04 06:17 am Sale | 13D | Entasis Therapeutics Holdings Inc. ETTX | Sofinnova Venture Partners IX L.P. | 0 0.000% | -1,180,178 (Position Closed) | View |
| 2021-02-16 3:07 pm Sale | 13G | Entasis Therapeutics Holdings Inc. ETTX | ARMISTICE CAPITAL LLC | 1,863,198 4.990% | -1,647,783 (-46.93%) | View |
| 2020-09-08 4:29 pm Purchase | 13G | Entasis Therapeutics Holdings Inc. ETTX | ARMISTICE CAPITAL LLC | 3,510,981 9.900% | 3,510,981 (New Position) | View |
| 2020-09-01 5:28 pm Purchase | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 37,345,794 69.000% | 9,345,794 (+33.38%) | View |
| 2020-08-31 3:10 pm Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 28,000,000 67.800% | 0 (Unchanged) | View |
| 2020-08-11 4:30 pm Sale | 13G | Entasis Therapeutics Holdings Inc. ETTX | Novo Holdings A/S | 1,173,896 4.300% | -1,007,947 (-46.20%) | View |
| 2020-07-09 4:48 pm Sale | 13D | Entasis Therapeutics Holdings Inc. ETTX | Clarus Lifesciences III L.P. | 1,339,836 4.900% | -283,569 (-17.47%) | View |
| 2020-06-18 12:30 pm Sale | 13D | Entasis Therapeutics Holdings Inc. ETTX | Frazier Life Sciences VIII L.P. | 799,953 2.900% | -250,000 (-23.81%) | View |
| 2020-06-16 1:54 pm Unchanged | 13G | Entasis Therapeutics Holdings Inc. ETTX | Novo Holdings A/S | 2,181,843 7.990% | 0 (Unchanged) | View |
| 2020-06-12 5:30 pm Purchase | 13D | Entasis Therapeutics Holdings Inc. ETTX | Innoviva Inc. INVA | 28,000,000 67.800% | 25,354,980 (+958.59%) | View |
| 2020-05-01 5:01 pm Unchanged | 13D | Entasis Therapeutics Holdings Inc. ETTX | Clarus Lifesciences III L.P. | 1,623,405 11.100% | 0 (Unchanged) | View |